Skip to main content
. 2021 May 1;10(9):1951. doi: 10.3390/jcm10091951

Table 1.

Demographic and clinical characteristics of enrolled population at baseline.

Total
n = 1538		 In-Hospital Mortality, n (%) p-Value
Variables [Number of Available Data] n (%) Yes
n = 422 (27%)		 No
n = 1116 (73%)
Sex (1533), n (%): 0.448
  • −

    F

 641 (42%) 183 (29%) 458 (71%)
  • −

    M

 892 (58%) 239 (27%) 653 (73%)
Age (1538), median (IQR): 74 (61–83) 83 (76–87) 69 (57–80) <0.001
Age distribution (1538), n (%): <0.001
 
  • -

    ≤50 y

 153 (10%) 4 (3%) 149 (97%)
 
  • -

    51–70 y

 490 (32%) 48 (10%) 442 (90%)
  • -

    71–80 y

 379 (24%) 116 (31%) 263 (69%)
  • -

    81–90 y

 413 (27%) 197 (48%) 216 (52%)
  • -

    >90 y

 103 (7%) 57 (55%) 46 (45%)
Smokers (1121), n (%): 0.033
  • -

    active

 76 (7%) 13 (17%) 63 (83%)
  • -

    former

 256 (23%) 83 (32%) 173 (68%)
  • -

    never smoked

 789 (70%) 223 (28%) 566 (72%)
Comorbidities (1538), n (%):
  • -

    Diabetes

 324 (21%) 120 (37%) 204 (63%) <0.001
  • -

    Hypertension

 759 (49%) 250 (33%) 509 (67%) <0.001
  • -

    Dementia

 309 (20%) 161 (52%) 148 (48%) <0.001
  • -

    Cardiovascular diseases

 490 (32%) 218 (44%) 272 (56%) <0.001
  • -

    Lung diseases

 <0.001
  • -

    COPD

 175 (11.4%) 84 (48%) 91 (52%)
  • -

    Asthma

 23 (1.5%) 5 (22%) 18 (78%)
  • -

    Other

 1 (0.1%) 1 (100%) 0 (0%)
Immunosuppression (1538), n (%): 148 (10%) 53 (36%) 95 (64%) 0.016
  • -

    Active solid tumors

 74 (5%) 31 (42%) 43 (58%) 0.004
  • -

    Blood cancers

 38 (2%) 12 (32%) 26 (68%) 0.558
  • -

    Immunosuppressive therapies, Transplanted patients

 21 (1%) 5 (24%) 16 (76%) 0.711
  • -

    Chronic steroidal use

 29 (2%) 9 (31%) 20 (69%) 0.657
  • -

    HIV

 1 (0.1%) 0 (0%) 1 (100%) 0.539
Symptoms at admission, n (%): 1249 (93%) 353 (28%) 896 (72%) 0.758
  • -

    fever (1346)

 1023 (76%) 270 (26%) 753 (74%) 0.005
  • -

    dyspnea (1346)

 719 (53%) 250 (35%) 469 (65%) <0.001
  • -

    myalgia (1346)

 221 (16%) 40 (18%) 181 (82%) <0.001
  • -

    sore throat (848)

 23 (3%) 4 (17%) 19 (83%) 0.152
  • -

    cough (1346)

 573 (43%) 105 (18%) 468 (82%) <0.001
  • -

    diarrhea (1346)

 172 (13%) 27 (16%) 145 (84%) <0.001
  • -

    no symptoms (1346)

 97 (7%) 26 (27%) 71 (73%) 0.758
Days from symptom onset to positive test (1248), median (IQR): 4 (1–8) 3 (0–6) 5 (2–9) <0.001
Days from symptoms onset to hospital admission (1445), median (IQR): 6 (2–10) 3 (0–7) 7 (3–10) <0.001
PaO2/FiO2 at admission (distribution) (1019), n (%): <0.001
  • -

    <200

 180 (18%) 114 (63%) 66 (37%)
  • -

    200–299

 412 (40%) 150 (36%) 262 (64%)
  • -

    ≥ 300

 427 (42%) 68 (16%) 359 (84%)
Pneumonia (1469), n (%): 1238 (84%) 355 (29%) 883 (71%) 0.074

COPD, chronic obstructive pulmonary disease; IQR, Inter Quartile Range; F, female; M, male; HIV, Human Immunodeficiency Virus.